CompletedNot Applicable

Selective Plasmofiltration for Abdominal Septic Shock: a Clinical Ctudy

Russia101 participantsStarted 2016-09-15

Plain-language summary

Group 1: 34 patients received prolonged hemodiafiltration (CVVHDF) on an emergency basis. Group 2: 35 patients received early isolated CVVHDF. Group 3: 32 patients received early combined extracorporeal detoxification (ECD) (selective plasma filtration \[SPF\] + CVVHDF). A comparative analysis of clinical and laboratory parameters was performed.

Who can participate

Age range

18 Years – 90 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Abdominal septic shock (Sepsis-3) and AKI stage 1 according to the KDIGO (Kidney Disease Improving Global Outcomes) classification Exclusion Criteria: Terminal state, active bleeding, atonic coma, severe heart failure (left ventricular ejection fraction \<25%), decompensated liver failure, body weight less than 20 kg, age under 18 years, pregnancy, as well as cases of septic shock without AKI.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

analysis of hospital mortality

Timeframe: hospital mortality from the moment of randomization (point 0) and then on 2,4,6,8,10,12,14 and 30 days

length of stay in the ICU

Timeframe: The duration of staying in the ICU, measured from the moment of randomization (point 0) and then until the moment of transfer to the specialized department on 2,4,6,8,10,12,14 and 30 days

Length of hospital stay

Timeframe: differences in the duration of hospitalization measured from the moment of randomization (point 0) and then on 2,4,6,8,10,12,14 and 30 days in days of staying in the clinic

Trial details

NCT IDNCT07121647

SponsorPirogov Russian National Research Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-02-20

View on ClinicalTrials.gov More Selective Plasma Filtration trials